Claims
- 1. A method for treating a condition or disorder that can be treated by decreasing intraocular pressure in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein Ar is benzoisothiazolyl or an oxide or dioxide thereof each optionally substituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; naphthyl optionally substituted by fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro; 3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or phthalazinyl; n is 1 or 2; and X and Y together with the phenyl to which they are attached form a cyclic ring system selected from quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; oxindolyl optionally substituted by spirocycloalkyl wherein said cycloalkyl moiety contains from 4 to 7 carbon atoms, or by one to three of (C1-C3)alkyl, or by one of chloro, fluoro or phenyl wherein said phenyl is optionally substituted by one chloro or fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl; benzoimidazolonyl; and benzotriazolyl.
- 2. A method for treating glaucoma or ischemic retinopathy in a mammal, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein Ar is benzoisothiazolyl or an oxide or dioxide thereof each optionally substituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; naphthyl optionally substituted by fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro; 3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or phthalazinyl; n is 1 or 2; and X and Y together with the phenyl to which they are attached form a cyclic ring system selected from quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; oxindolyl optionally substituted by spirocycloalkyl wherein said cycloalkyl moiety contains from 4 to 7 carbon atoms, or by one to three of (C1-C3)alkyl, or by one of chloro, fluoro or phenyl wherein said phenyl is optionally substituted by one chloro or fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl; benzoimidazolonyl; and benzotriazolyl.
- 3. A method according to claim 2, wherein said method is for the treatment of glaucoma.
- 4. A method according to claim 2, wherein said method is for the treatment of ischemic retinopathy.
- 5. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is adminstered is one wherein X and Y, together with the phenyl to which they are attached, form a benzoxazolonyl group.
- 6. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is administered is one wherein Ar is benzoisothiazolyl and n is 1.
- 7. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is administered is one wherein X and Y, together with the phenyl to which they are attached, form an oxindole that is optionally substituted by chloro, fluoro or phenyl.
- 8. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is adminstered is one wherein Ar is naphthyl and n is 1.
- 9. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is administered is ziprasidone or a pharmaceutically acceptable salt of ziprasidone.
- 10. A method according to claim 2, wherein the compound or pharmaceutically acceptable salt that is administered is ziprasidone mesylate trihydrate or ziprasidone hydrochloride monohydrate.
Parent Case Info
This application claims priority under 35 U.S.C. § 119(e) from U.S. Provisional Application Serial No. 60/085,867, filed May 18, 1998 and from U.S. Provisional Application Serial No. 60/086,745, filed May 26, 1998.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4831031 |
Lowe, III et al. |
May 1989 |
A |
5196434 |
Taverne et al. |
Mar 1993 |
A |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/085867 |
May 1998 |
US |
|
60/086745 |
May 1998 |
US |